Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given a consensus rating of “Moderate Buy” by the four analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $98.75.

A number of equities research analysts recently weighed in on the company. StockNews.com cut Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. Canaccord Genuity Group reiterated a “buy” rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. Finally, DA Davidson boosted their target price on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Opal Wealth Advisors LLC acquired a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at about $26,000. Principal Securities Inc. acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at approximately $29,000. Quest Partners LLC raised its position in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Prestige Consumer Healthcare during the second quarter worth $35,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 0.2 %

PBH opened at $73.55 on Wednesday. The company has a market capitalization of $3.65 billion, a PE ratio of 17.64, a price-to-earnings-growth ratio of 2.06 and a beta of 0.48. The firm has a 50-day simple moving average of $70.98 and a two-hundred day simple moving average of $69.61. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a 52 week low of $56.34 and a 52 week high of $75.80.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.04. The company had revenue of $267.10 million for the quarter, compared to analysts’ expectations of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.06 earnings per share. Analysts forecast that Prestige Consumer Healthcare will post 4.42 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.